Literature DB >> 31377222

Effects and mechanisms of QiShenYiQi pills and major ingredients on myocardial microcirculatory disturbance, cardiac injury and fibrosis induced by ischemia-reperfusion.

Jing-Yan Han1, Quan Li2, Chun-Shui Pan2, Kai Sun2, Jing-Yu Fan2.   

Abstract

Coronary heart disease remains a major threaten for public health worldwide, and pharmacological or mechanical coronary reperfusion are currently used for treatment of acute coronary syndrome. However, restoration of blood flow to ischemic myocardium leads to ischemia/reperfusion (I/R) injury. Microcirculatory disturbance and cardiac injury after I/R occur via a complex pathologic process including metabolism impairment in the ischemia phase and oxidative stress in the reperfusion phase. Obviously, any treatment targeting a single link is insufficient to cope with I/R injury. Investigation in the past decade in our laboratory as well as in other's demonstrated the cardioprotection potential of QiShenYiQi Pills (QSYQ) and ingredients in experimental animal models of I/R injury. These results have offered insight into the mechanism thereby QSYQ prevents against cardiac I/R injury in clinic. This review will outline the results with respect to the effect of QSYQ and major bioactive ingredients on I/R-induced microcirculatory disturbance, cardiac injury and fibrosis, with emphasis on the underlying mechanisms.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemokine; Energy metabolism; Macrophages; Oxidative stress; Smad

Mesh:

Substances:

Year:  2019        PMID: 31377222     DOI: 10.1016/j.phrs.2019.104386

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

Review 1.  Research on natural products from traditional Chinese medicine in the treatment of myocardial ischemia-reperfusion injury.

Authors:  Wenyu Bu; Zhaoyang Zhang; Dickson Kofi Wiredu Ocansey; Zhihua Yu; Xiao Yang; Zhitong Liu; Xinyu Wang; Yuhe Ke
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Protective Effects of Ischemic Postconditioning on Livers in Rats with Limb Ischemia-Reperfusion via Glycogen Synthase Kinase 3 beta (GSK-3β)/Fyn/Nuclear Receptor-Erythroid-2-Related Factor (Nrf2) Pathway.

Authors:  Qibing Niu; Wanli Sun; Quan Chen; Yang Long; Wanjun Cao; Shiqi Wen; Anqiang Li; Fang Dong; Hao Shi
Journal:  Med Sci Monit       Date:  2020-07-20

3.  Galectin-3 Mediated Inflammatory Response Contributes to Neurological Recovery by QiShenYiQi in Subacute Stroke Model.

Authors:  Yule Wang; Shuang He; Xinyan Liu; Zhixiong Li; Lin Zhu; Guangxu Xiao; Xiaoli Du; Hongxia Du; Wen Zhang; Yiqian Zhang; John Orgah; Yuxin Feng; Boli Zhang; Yan Zhu
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

4.  Mettl14 Attenuates Cardiac Ischemia/Reperfusion Injury by Regulating Wnt1/β-Catenin Signaling Pathway.

Authors:  Ping Pang; Zhezhe Qu; Shuting Yu; Xiaochen Pang; Xin Li; Yuelin Gao; Kuiwu Liu; Qian Liu; Xiuzhu Wang; Yu Bian; Yingqi Liu; Yingqiong Jia; Zhiyong Sun; Hanif Khan; Zhongting Mei; Xiaoqian Bi; Changhao Wang; Xinda Yin; Zhimin Du; Weijie Du
Journal:  Front Cell Dev Biol       Date:  2021-12-16

5.  QiShenYiQi Inhibits Tissue Plasminogen Activator-Induced Brain Edema and Hemorrhage after Ischemic Stroke in Mice.

Authors:  Yang Ye; Quan Li; Chun-Shui Pan; Li Yan; Kai Sun; Xiao-Yi Wang; Shu-Qi Yao; Jing-Yu Fan; Jing-Yan Han
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.810

6.  Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation.

Authors:  Guligena Sawuer; Xue-Kuan Ma; Ya-Jie Zhang; Xuan-Ming Zhang; Zulihumaer Ainiwaer; Dong-Qing An
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-02       Impact factor: 2.629

7.  QishenYiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology.

Authors:  Meng Li; Yueyao Wang; Zhongwen Qi; Zhuo Yuan; Shichao Lv; Yawei Zheng; Zhipeng Yan; Mingyang Wang; Huanjie Fu; Xinbiao Fan; Nan Ji; Ming Liu; Zhuyuan Fang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

8.  The Composite of 3, 4-Dihydroxyl-Phenyl Lactic Acid and Notoginsenoside R1 Attenuates Myocardial Ischemia and Reperfusion Injury Through Regulating Mitochondrial Respiratory Chain.

Authors:  Li Yan; Chun-Shui Pan; Yu-Ying Liu; Yuan-Chen Cui; Bai-He Hu; Xin Chang; Xiao-Hong Wei; Ping Huang; Jian Liu; Jing-Yu Fan; Quan Li; Kai Sun; Lu-Lu Yan; Ke He; Jing-Yan Han
Journal:  Front Physiol       Date:  2021-07-12       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.